Danon Disease
Definition
Danon disease is a rare X-linked dominant lysosomal storage disorder caused by loss-of-function variants in LAMP2 (lysosomal-associated membrane protein 2), a mediator of lysosomal-dependent autophagy. LAMP2 deficiency causes accumulation of autophagic vacuoles in cardiomyocytes and skeletal muscle cells, leading to severe hypertrophic cardiomyopathy (HCM), skeletal myopathy, and variable neurocognitive deficits. In males, the disease is rapidly fatal without intervention; typical age at death or cardiac transplantation is 19–21 years.
Key Concepts
Pathophysiology
- LAMP2 protein: Mediates autophagosome–lysosome fusion; LAMP2B isoform (one of 3 splice-generated isoforms) contributes most substantially to cardiomyocyte autophagy
- Loss of LAMP2 → autophagic vacuole accumulation → myofibrillar disarray → progressive fibrosis and severe hypertrophy
- LAMP2B deletion in hiPSC-derived cardiomyocytes confirmed impaired autophagy, reversed by genetic correction (sources/aav9-danon-nejm-2025, rating: high)
Natural History and Sex Differences
- Males: X-linked hemizygosity → complete LAMP2 loss → severe HCM (median LVM index ~98 g/m²·⁷ at presentation); median age at diagnosis of cardiac hypertrophy ~13 years; typical transplantation or death age 19–21 years; skeletal myopathy and neurocognitive deficits more frequent than in females
- Females: X-linked dominant with variable penetrance; broader age range at presentation; heart failure and death from adolescence to ~50 years; cardiac phenotype more heterogeneous (sources/aav9-danon-nejm-2025, rating: high)
- Cardiac arrhythmias: All patients have abnormal ECG at presentation — increased QRS voltage, intraventricular conduction delay or block, and/or ventricular preexcitation (Wolff-Parkinson-White syndrome in a substantial proportion)
- ICD limitations: Extreme hypertrophy may prevent consistent arrhythmia termination
- Heart transplantation: Prolongs life but associated with rejection, vasculopathy, opportunistic infection, renal insufficiency, and cancer risk; not curative
Cardiac Biomarker Profile
- Markedly elevated cardiac troponin I at baseline (median 0.86 ng/mL; ULN 0.04 ng/mL) — reflecting ongoing myocardial injury from autophagic vacuole accumulation
- Variably elevated BNP and NT-proBNP — reflecting myocardial wall stress from hypertrophy
- Annual LVM increases ~8% (untreated natural history data) (sources/aav9-danon-nejm-2025, rating: high)
Gene Therapy — RP-A501 (rAAV9-LAMP2B)
- RP-A501 (Rocket Pharmaceuticals): Recombinant AAV9 carrying full-length LAMP2B transgene; single IV infusion
- Doses studied: low-dose 6.7×10¹³ gc/kg (adults/adolescents and pediatric); high-dose 1.1×10¹⁴ gc/kg (adults/adolescents only)
- Immunomodulatory regimen required: prednisone + tacrolimus or sirolimus + rituximab (targeting complement activation and cellular immunity to AAV capsid)
- Phase 1 results (n=7 males; 24–54 months; NEJM 2025):
- 7/7 alive at data cutoff (~4.5 years)
- In 6 patients with LVEF ≥40% at baseline: LAMP2 protein confirmed in endomyocardial biopsy at 12 months (6/6) and 24–36 months (5/6)
- LVM index: median −23% (range −7 to −48%) over 24–54 months; 5/6 had ≥10% reduction at 12 months; pediatric response seen as early as 6 months
- Troponin I: median −84% (range −33 to −99%)
- Natriuretic peptides: median −57% (range −93 to +16%)
- NYHA class and KCCQ-12 (≥5-point improvement = clinically meaningful) improved in all 6 evaluable patients
- Adult patients now aged 21–24 years — beyond the typical Danon disease transplant/death age (sources/aav9-danon-nejm-2025, rating: high)
- Durability of expression: Vector copy number and LAMP2B RNA largely sustained up to 4.5 years; adult/adolescent cardiomyocytes are non-dividing → minimal episomal dilution (contrast with infant Pompe disease where dilution is a concern)
- Phase 2 registrational trial ongoing: NCT06092034; dose 6.7×10¹³ gc/kg; males ≥8 years
Safety Profile of AAV9 in Danon Disease
- Complement-mediated TMA (grade 4): Occurred in Patient 5 (high-dose adult, LVEF 32% at baseline); complement activation driven by anti-capsid antibodies; resulted in thrombocytopenia and AKI requiring RRT → full recovery within 4 weeks; patient required transplantation at 5 months
- Clinical response: LVEF <40% added as exclusion criterion
- Complement monitoring: sC5b-9 complex elevated more in adults than pediatric patients; pediatric patients (n=2) had no treatment-related serious AEs
- Glucocorticoid-induced skeletal myopathy (grade 3): Exacerbation of underlying Danon myopathy in 3 adult patients; resolved with glucocorticoid discontinuation — a major practical challenge given the mandatory immunomodulatory regimen
- Salmonella sepsis (grade 3): From immunosuppression; resolved
- Anti-LAMP2B antibodies: Detected in several patients without clinical immunological sequelae; no LAMP2B-specific T-cell response — contrasts with Pompe/GC301 where no anti-GAA antibodies developed at all
Immunomodulation Requirements and Implications
- All patients required a 3-drug immunomodulatory regimen (prednisone + calcineurin inhibitor + rituximab)
- The regimen itself caused grade 3 AEs (myopathy, sepsis, DVT) — significant in a patient population with pre-existing skeletal myopathy
- Pediatric patients showed lower complement activation and no serious treatment-related AEs — potentially favorable pharmacokinetic/immunological profile at lower body mass
- Contrast with Pompe/GC301: No immunomodulatory regimen was used beyond prophylactic prednisolone; no anti-GAA antibodies emerged in any patient — the immunological challenge appears disease/vector-dependent
Contradictions / Open Questions
- Anti-LAMP2B antibodies vs. no anti-GAA in Pompe: RP-A501 (Danon) induced anti-LAMP2B antibodies in several patients (without clinical sequelae); GC301 (Pompe) induced no anti-GAA antibodies in any patient. Why transgenic LAMP2B triggers binding antibodies while transgenic GAA does not is unclear — may relate to differences in hepatic expression levels, immune tolerance mechanisms, or host LAMP2B protein presence in females (females may express some residual LAMP2B through X-inactivation mosaicism, but male patients should have none) (sources/aav9-danon-nejm-2025, rating: high)
- Patient 1 — LAMP2 protein loss at 24–36 months: Vector DNA and RNA persisted; autophagic vacuoles remained reduced; clinical benefit continued through 54 months. Whether protein loss represents immune-mediated clearance of transgenic LAMP2B protein (subclinical antibody-driven), assay limitations, or real loss of expression without clinical correlate is unresolved (sources/aav9-danon-nejm-2025, rating: high)
- Complement-mediated TMA risk stratification: Grade 4 TMA occurred only in the high-dose adult patient with low LVEF. Whether this reflects dose, LVEF, age, or antibody pre-load is unclear. The now-mandatory LVEF ≥40% exclusion and low-dose standardisation for Phase 2 is pragmatic but not mechanistically justified (sources/aav9-danon-nejm-2025, rating: high)
- Skeletal myopathy not addressed by cardiac-dose therapy: The cardiac gene therapy dose is insufficient to correct skeletal muscle disease in Danon disease, and the required glucocorticoids worsen pre-existing myopathy. This creates a therapeutic paradox: effective cardiac treatment may temporarily worsen the extracardiac phenotype (sources/aav9-danon-nejm-2025, rating: high)
- Durability beyond 4.5 years: Follow-up ongoing. Adult cardiomyocyte non-dividing biology predicts sustained episomal expression, but long-term immune surveillance, inflammatory triggers, and potential protein-level waning need continued monitoring
- Female patients: Entirely excluded from this study due to phenotypic heterogeneity. Whether the same AAV9 strategy is effective, safe, or feasible in females with Danon disease is unknown
Connections
- Related to concepts/AAV-Gene-Delivery
- Related to concepts/Pompe-Disease (parallel lysosomal storage disorder with AAV9 gene therapy data)
- Related to concepts/Arrhythmogenic-Cardiomyopathy (Danon disease is a phenotypic mimic of HCM; WPW association)
- Related to concepts/Genetic-Testing-in-Cardiomyopathy